Drug intelligence / Profile preview

vialinin a

Development stage
Preclinical
Modality
Small Molecules
Administration
Unknown
01

Overview

Vialinin A is a natural p-terphenyl compound isolated from edible mushrooms, notably *Thelephora vialis* and *Thelephora terrestris*. It acts as a potent inhibitor of several deubiquitinating enzymes, most notably ubiquitin-specific peptidase 4 (USP4), USP5/isopeptidase T, and UCH-L1, with reported IC50 values of 1.5 μM (USP4), 5.9 μM (USP5/isopeptidase T), and 22.3 μM (UCH-L1)[1][2][3]. Vialinin A exhibits anti-inflammatory, antioxidant, anti-allergic, and antiangiogenic activities. It inhibits release of tumour necrosis factor alpha (TNF-α), interleukin 4, β-hexosaminidase, and monocyte chemotactic protein 1 in mast cells, and suppresses the production of angiogenic cytokines (e.g., angiopoietin-2, G-CSF, HB-EGF, HGF) in human vascular endothelial cells[1][3][4]. It blocks VEGF-induced neovascularization both in vitro and in vivo, primarily by inhibiting ROS generation and NF-κB nuclear translocation, and reduces inflammation and fibrosis by regulating the Rheb/mTOR signaling pathway[2][4].

Brand names
vialinin a
Other names
vialinin ap-terphenyl antioxidant
02

Targets

UCHL1 (Ubiquitin carboxyl-terminal hydrolase 1)USP5 (Ubiquitin carboxyl-terminal hydrolase 5)USP4

Beyond the preview

Go deeper on vialinin a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on vialinin a.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call